Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262113 · ClinicalTrials.gov registry record · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
A NA study of Neurofibromatosis 1, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 294
- Enrollment target
- 1
- Study location
NCT06262113 is a NA study of Neurofibromatosis 1 that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 294 participants, below the 1,023-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06262113, a NA study of Neurofibromatosis 1, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 294 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this fully decentralized, randomized controlled trial is to compare the efficacy of two educational interventions for individuals with Neurofibromatosis 1 (NF1). The primary objective of the study is to determine which intervention leads to higher rates of evidenced-based health screenings for NF1 patients in primary care settings. Adults with NF1 and parents/guardians of children with NF1 from across the U.S. who do not go to a specialized NF clinic and who have an upcoming annual wellness visits (e.g. an annual physical, a well-child visit, etc.) scheduled with a primary care provider (PCP) are eligible to enroll in the study. To see if you might be eligible, fill out a prescreening survey here: https://redcap.link/mynfguide
Conditions Studied
Interventions
- OTHER Letters about NF1 Care (Content Type 1)
- OTHER Letters about NF1 Care (Content Type 2)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2026-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06262113
The ClinicalTrials.gov registry entry for NCT06262113 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,023-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (71% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 2 interventions - of which Letters about NF1 Care (Content Type 1) is the first listed.
NCT06262113 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06262113 about?
NCT06262113 is a clinical study titled "A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1". The goal of this fully decentralized, randomized controlled trial is to compare the efficacy of two educational interventions for individuals with Neurofibromatosis 1 (NF1). The primary objective of the study is to determine which intervention leads to higher rates of evidenced-based health screenin...
What is the current status of trial NCT06262113?
This trial is currently recruiting. It is a NA study. The enrollment target is 294 participants. The study started on 2024-12-03. Estimated completion is 2026-08.
What conditions does trial NCT06262113 study?
This clinical trial studies the following conditions: Neurofibromatosis 1.
What interventions are being tested in trial NCT06262113?
The interventions under investigation include: Letters about NF1 Care (Content Type 1) (OTHER), Letters about NF1 Care (Content Type 2) (OTHER).
Who is sponsoring clinical trial NCT06262113?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06262113 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
RECRUITING · NA
-
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
RECRUITING · NA
-
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
ACTIVE NOT RECRUITING · NA
-
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
RECRUITING
-
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.